Safer contraception? new pill aims to lower artery risks
NCT ID NCT07536763
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial compares a new combined oral contraceptive pill (estetrol-drospirenone) to a standard one (ethinylestradiol-levonorgestrel) in 98 women aged 18-49. Researchers will measure artery function, blood pressure, and metabolic markers over 12 months to see if the new pill has fewer vascular risks. The goal is to find a safer contraceptive option.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Estetrol-drospirenone (a new combined oral contraceptive pill)
- What this could lead to
- If it works, this could show that the new pill is safer for the heart and blood vessels than current options, offering a better choice for contraception.
- What could go wrong
- This is a small, early-phase trial (98 participants) comparing two pills, not testing a cure. Results may not apply to all women, and the new pill could still carry risks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONTRACEPTION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Texts and local mentors: a new way to empower teen girls on contraception?
- Could a single implant replace the morning-after pill?
- New condom materials put to the test: can plastic beat latex?
- New birth control pill aims to cut estrogen while boosting effectiveness
- Village women trained as mentors to help others take charge of birth control decisions
- Your DNA could determine if your birth control works